Clinical Trial Update: Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing nilotinib versus standard imatinib in chronic-phase chronic myeloid leukemia; study evaluated kinetics of complete molecular response us…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib (imatinib)
• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: CHRONIC MYELOGENOUS LEUKEMIA | Phase 3 | Status: COMPLETED | Results posted: 2016-08-16